137 related articles for article (PubMed ID: 38885453)
1. ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review.
Kathuria-Prakash N; Lopez LP; Raman S; Ye H; Anaokar J; Sisk A; Pantuck AJ; Drakaki A
JCO Precis Oncol; 2024 Jun; 8():e2400154. PubMed ID: 38885453
[TBL] [Abstract][Full Text] [Related]
2. Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.
Pal SK; Bergerot P; Dizman N; Bergerot C; Adashek J; Madison R; Chung JH; Ali SM; Jones JO; Salgia R
Eur Urol; 2018 Jul; 74(1):124-128. PubMed ID: 29685646
[No Abstract] [Full Text] [Related]
3. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
Shiihara J; Ohyanagi F; Amari H; Toda M; Tahara H; Yuzawa M; Maeda Y; Nomura M; Mizushina Y; Nagai Y; Ohta H; Yamaguchi Y
Thorac Cancer; 2021 Sep; 12(17):2420-2423. PubMed ID: 34324792
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib.
Reed DR; Hall RD; Gentzler RD; Volodin L; Douvas MG; Portell CA
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e247-e250. PubMed ID: 30992232
[No Abstract] [Full Text] [Related]
5. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
[TBL] [Abstract][Full Text] [Related]
6. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
Hayashi N; Fujita A; Saikai T; Takabatake H; Sotoshiro M; Sekine K; Kawana A
Intern Med; 2018 Mar; 57(5):713-716. PubMed ID: 29151522
[TBL] [Abstract][Full Text] [Related]
7. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
8. Impact of ALK Inhibitors in Patients With
Takeyasu Y; Okuma HS; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Shimoi T; Noguchi E; Arakawa A; Mori T; Sunami K; Kubo T; Kohno T; Akihiko Y; Yamamoto N; Yonemori K
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036223
[TBL] [Abstract][Full Text] [Related]
9. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
[TBL] [Abstract][Full Text] [Related]
10. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
[TBL] [Abstract][Full Text] [Related]
11. Identification of anaplastic lymphoma kinase fusion in clear cell renal carcinoma (ALK-tRCC): a precision oncology medicine case report.
Varchetta V; Campanella C; Rossi M; Verzaro R; Vitale M; Soda G; Mancuso A
Recenti Prog Med; 2021 Jan; 112(1):14e-15e. PubMed ID: 33512368
[TBL] [Abstract][Full Text] [Related]
12. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
13. Genetic analysis and clinicopathological features of ALK-rearranged renal cell carcinoma in a large series of resected Chinese renal cell carcinoma patients and literature review.
Yu W; Wang Y; Jiang Y; Zhang W; Li Y
Histopathology; 2017 Jul; 71(1):53-62. PubMed ID: 28199742
[TBL] [Abstract][Full Text] [Related]
14.
Wangsiricharoen S; Zhong M; Ranganathan S; Matoso A; Argani P
Int J Surg Pathol; 2021 Oct; 29(7):808-814. PubMed ID: 33729862
[TBL] [Abstract][Full Text] [Related]
15. ALK-rearranged renal cell carcinomas in Polish population.
Gorczynski A; Czapiewski P; Korwat A; Budynko L; Prelowska M; Okon K; Biernat W
Pathol Res Pract; 2019 Dec; 215(12):152669. PubMed ID: 31677810
[TBL] [Abstract][Full Text] [Related]
16. Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report.
Sun K; Nie L; Nong L; Cheng Y
Thorac Cancer; 2021 Jun; 12(12):1927-1930. PubMed ID: 33960639
[TBL] [Abstract][Full Text] [Related]
17. Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
Hu J; Zhang B; Yao F; Fu Y; Chen D; Li D; Du N; Lizaso A; Song J; Zhang L; Li X
Ther Adv Respir Dis; 2020; 14():1753466620935770. PubMed ID: 32600123
[No Abstract] [Full Text] [Related]
18. Anaplastic Lymphoma Kinase Mutation (
Carneiro BA; Pamarthy S; Shah AN; Sagar V; Unno K; Han H; Yang XJ; Costa RB; Nagy RJ; Lanman RB; Kuzel TM; Ross JS; Gay L; Elvin JA; Ali SM; Cristofanilli M; Chae YK; Giles FJ; Abdulkadir SA
Clin Cancer Res; 2018 Jun; 24(12):2732-2739. PubMed ID: 29559559
[No Abstract] [Full Text] [Related]
19. Targeted Therapy for Mutation-Driven Metastatic Non-Small-Cell Lung Cancer: Considerations for ALK-Rearranged Tumors.
Mileham KF; Ahmad MN; Kim ES
Oncology (Williston Park); 2019 Apr; 33(4):152-5. PubMed ID: 30990569
[No Abstract] [Full Text] [Related]
20. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
Koyama K; Katsurada N; Jimbo N; Tachihara M; Tamura D; Nakata K; Nagano T; Yamamoto M; Kamiryo H; Kobayashi K; Itoh T; Nishimura Y
Pathol Int; 2019 May; 69(5):294-299. PubMed ID: 30900377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]